Alto Neuroscience Publishes Prime-Praxol Study Results
Alto Neuroscience highlighted the publication in Nature Medicine of Prime-Praxol, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund University, Sweden. Adults with elevated baseline anhedonia symptoms with a diagnosis of major depressive disorder, dysthymia, or bipolar depression were randomized to flexible-dose pramipexole or placebo, added to ongoing treatment, for nine weeks, followed by a six-month open-label extension period. On the primary endpoint, pramipexole reduced anhedonia significantly more than placebo on the Snaith-Hamilton Pleasure Scale, with significant improvements on independent measures of anhedonia and apathy with improvements maintained through a six-month open-label treatment period.
